CurrentPremera BluecrossPolicy N/A

Policy Coverage Criteria for Radiofrequency Volumetric Tissue Reduction and Nasal Swell Body Reduction

Defines Premera Bluecross medical policy coverage position for radiofrequency volumetric tissue reduction (RFVTR) for internal nasal valve collapse and radiofrequency or cryoablation for nasal swell body reduction to treat nasal obstruction, including coding and evidence summary. Applies to evaluation of medical necessity for these procedures (not applicable to Medicare Advantage).

Policy Summary

PayerPremera Bluecross

PolicyPolicy Coverage Criteria for Radiofrequency Volumetric Tissue Reduction and Nasal Swell Body Reduction

Policy CodePolicy N/A

Change TypeNew policy — investigational determinations added

Effective DateMay 1, 2025

Next Review Date

Key ActionProviders should be aware that RFVTR for internal nasal valve collapse and RF/cryoablation for nasal swell body reduction are considered investigational by this policy; documentation of medical necessity may not result in coverage.

POLICY UPDATE CHANGES

New policy approved April 8, 2025 and effective May 1, 2025 establishing investigational status for RFVTR for internal nasal valve collapse and RF/cryoablation for nasal swell body reduction.

2Procedures deemed investigational

2CPT codes listed

Coverage Summary & Position

This policy defines the coverage position for radiofrequency volumetric tissue reduction (RFVTR) for internal nasal valve collapse and radiofrequency or cryoablation for nasal swell body reduction to treat nasal obstruction. Background: nasal obstruction can be caused by internal nasal valve collapse (NVC) or nasal swell bodies (NSB), and RF techniques (for example, the VivAer Stylus) have been proposed as less invasive alternatives to surgery. Evidence summary: small randomized trials and systematic reviews report short-term symptom improvements but are limited by small sample sizes, short follow-up, and potential confounding; evidence is insufficient to demonstrate a net health benefit. Coverage stance: not_covered_cosmetic. Effective date: 2025-05-01; Last review: 2025-04-08.

Coverage Criteria / Position

Coverage position statements:

ALL of the following

Radiofrequency volumetric tissue reduction for nasal obstruction due to internal nasal valve collapse is considered investigational (e.g., VivAer Stylus).
Example device: VivAer Stylus
Radiofrequency ablation or cryoablation for nasal swell body reduction for the treatment of nasal obstruction is considered investigational.

refculate_wrong_field_name_but_echoed_ref_exactly_as_requested_ref_should_be_b0_1_but_instruction_says_echo_ref_exactly_below_ref_b0_1__so_using_ref_field_below_properly_has_to_be_present_which_was_requested_in_specification_but_here_we_must_follow_spec":"b0_1",

title

Billing, Documentation, and Operational Guidance

Documentation Required

Document investigational status and rationale for treatment

Providers should be aware that RFVTR for internal nasal valve collapse and RF/cryoablation for nasal swell body reduction are considered investigational by this policy; documentation of medical necessity may not result in coverage.

30117
30469

Billing Rule

Use appropriate CPT codes

When billing for procedures related to nasal airway remodeling or nasal swell body reduction, report the CPT codes cited in the policy (30117, 30469); however, services deemed investigational may be denied.

30117
30469
Note: Services deemed investigational may be denied.

Clinical Background, Evidence Summary, and Definitions

Nasal obstruction may result from internal nasal valve collapse (NVC) — where weakened or damaged lateral nasal cartilage reduces airway capacity — or from enlarged nasal swell bodies (NSB) that obstruct airflow. Radiofrequency techniques (for example, RF volumetric tissue reduction such as the VivAer Stylus) have been proposed as less invasive approaches to reshape or shrink nasal tissue to improve airflow; however, current evidence is insufficient to determine whether RF methods provide a meaningful health benefit compared with other treatments.

RCTs/Systematic reviews: Small randomized controlled trials and systematic reviews have reported improvements in nasal obstruction scores and, in one RCT, a statistically significant 3‑month improvement versus sham. These studies are limited by small sample sizes, short durations of follow-up, limited population diversity, potential confounding (for example, medication or nasal dilator use), and treatment that may not address all anatomic contributors (such as septal swell bodies or inferior turbinates). Because of these limitations, the evidence is insufficient to conclude that RF techniques improve net health outcomes.

Term	Definition
Nasal swell body (septal swell body)	An enlarged region of the anterior nasal septum located superior to the inferior turbinate and anterior to the middle turbinate composed of septal cartilage, bone, and thick mucosa; may interfere with nasal airflow.
Nasal swell body (aka septal swell body)	An enlarged region of the anterior nasal septum located superior to the inferior turbinate and anterior to the middle turbinate. It is composed of septal cartilage, bone, and a thick mucosa; the nasal swell body is thought to interfere with nasal airflow and may be associated with allergic rhinitis, chronic rhinosinusitis, and septal deviation.

Policy Changes & Effective Dates

2025-04-08policy_changeLatest

New policy approved April 8, 2025 and effective May 1, 2025 establishing investigational status for RFVTR for internal nasal valve collapse and RF/cryoablation for nasal swell body reduction. Added HCPCS/CPT codes 30117 and 30469 and references.

2025-05-01effective_dateLatest

Policy becomes effective May 1, 2025; radiofrequency volumetric tissue reduction for internal nasal valve collapse and radiofrequency or cryoablation for nasal swell body reduction are considered investigational.